Zydus Lifesciences Profit Drops 36% Despite Revenue Growth

• Zydus Lifesciences’ first-quarter net profit declined 35.9% to ₹9.40 billion, despite strong revenue growth.
• Revenue from operations increased 22% to ₹80.17 billion, supported by India formulations, international markets and consumer wellness.
• EBITDA fell 7.6%, while the EBITDA margin narrowed sharply to 24.1% from 31.8% a year earlier.

India-based Zydus Lifesciences reported a 35.9% decline in consolidated net profit for the quarter ended June 30, 2026, as rising research, operating and acquisition-related costs outweighed growth across several businesses.

Net profit fell to ₹9.398 billion in the first quarter of fiscal 2027 from ₹14.668 billion a year earlier. Revenue from operations rose 22% to ₹80.170 billion, according to the company’s first-quarter financial disclosure.

Zydus did not issue new annual revenue or profit guidance with the quarterly results. The absence of a revised forecast means there is no new company outlook to compare with its previous expectations.

No sufficiently reliable analyst consensus covering the reported quarter was available at publication. The results are therefore presented against the previous-year and preceding-quarter figures rather than described as a beat or miss.

Higher expenses reduce operating profitability

Consolidated earnings before interest, taxes, depreciation and amortisation, or EBITDA, declined 7.6% to ₹19.294 billion from ₹20.885 billion in the corresponding quarter.

The EBITDA margin contracted by 770 basis points to 24.1%, compared with 31.8% a year earlier. Sequentially, EBITDA dropped 24.5%, while the margin declined from 33.7% in the March quarter.

Profit before tax fell 32% year over year to ₹13.066 billion. Compared with the preceding quarter, revenue increased 5.7%, but net profit declined 26.1%.

Total expenses increased faster than revenue, rising about 41% from a year earlier. Research and development expenditure climbed by more than 32%, while other operating expenses increased approximately 48%, according to the reported financial data.

Zydus invested ₹6.424 billion in research and development during the quarter, equivalent to 8% of revenue. Organic capital expenditure reached ₹5.852 billion.

The company reported a net debt-to-equity ratio of 0.22 times at June 30 and net debt equivalent to 0.70 times EBITDA.

“FY27 is off to a strong, profitable start,” Managing Director Sharvil Patel said in the company’s results statement. “Our branded portfolio now exceeds 55% of revenues.”

Patel added that branded products represented 11% of US sales and said their contribution was expected to increase with the planned launch of saroglitazar. The US Food and Drug Administration has granted priority review to the drug’s application for treating primary biliary cholangitis.

India and international formulations support growth

Pharmaceutical-business sales increased 8.6% to ₹60.900 billion and accounted for 78% of consolidated business revenue.

India formulations revenue rose 19.5% to ₹18.158 billion, supported by growth across chronic, acute and super-specialty therapies. The company said it grew faster than the Indian pharmaceutical market in cardiology, diabetology, gynaecology, anti-infectives and pain management, as well as oncology and nephrology.

Zydus’ chronic and sub-chronic portfolio represented 54.2% of domestic formulations sales, an increase of 360 basis points over four years, based on AWACS data for the 12 months through June 2026.

International-markets formulations revenue advanced 34% to ₹9.735 billion. Zydus attributed the increase to demand across markets and execution of its commercial plans.

Active pharmaceutical ingredient sales rose 14.5% to ₹1.804 billion. Revenue from alliances and other activities declined 11.1% to ₹224 million.

North America declines despite new product launches

North America formulations remained the largest pharmaceutical unit, representing 40% of consolidated business revenue. However, sales declined 2.6% to ₹30.979 billion, reflecting continued competitive pressure in the US generics market.

In constant-currency terms, North American revenue reached $327 million. The business nevertheless improved 4.9% from the preceding quarter.

Zydus filed five abbreviated new drug applications in the United States during the quarter, received nine approvals—including four tentative approvals—and introduced 11 products.

The company also launched NUFYMCO, its first US biosimilar, and completed its acquisition of Assertio Holdings. The transaction expanded Zydus’ presence in branded and specialty pharmaceuticals but also increased the group’s financing and integration requirements.

Competition and price erosion remain significant risks for Indian generic-drug manufacturers operating in the United States. Zydus’ North American performance broadly reflected the restrained US sales reported by some of its Indian pharmaceutical peers during the quarter.

Consumer wellness expands after acquisition

Consumer wellness revenue surged 67.2% to ₹14.292 billion, partly reflecting the inclusion of the acquired Comfort Click business. The division contributed 18% of consolidated business revenue.

On a like-for-like basis, the international wellness business, including Comfort Click, grew 25%. Domestic wellness revenue increased 5%, as growth in skin and hair care and food and nutrition products was partly offset by weaker seasonal-product demand during a softer summer.

MedTech contributed ₹2.828 billion, compared with only ₹20 million in the year-earlier quarter, following Zydus’ expansion into medical technology. The business accounted for 4% of consolidated revenue.

Zydus shares were trading about 7% higher during the August 11 session, according to intraday market data. Because much of the advance began before the results were published, the movement cannot be attributed solely to the quarterly announcement.

The company’s outlook will depend on its ability to contain research and operating costs while integrating recent acquisitions. Additional risks include US generic-price competition, regulatory scrutiny, foreign-exchange movements and the commercial performance of specialty-product launches.

Zydus Lifesciences develops, manufactures and markets generic medicines, branded pharmaceuticals, biologics, vaccines, active pharmaceutical ingredients and wellness products. The Ahmedabad-headquartered group employs more than 29,000 people and operates across India, North America and international markets.

—

Frequently asked questions